DWV Stock Overview A medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for ANGLE Historical stock prices Current Share Price UK£0.13 52 Week High UK£0.26 52 Week Low UK£0.065 Beta 0.23 1 Month Change 9.84% 3 Month Change 77.48% 1 Year Change -33.00% 3 Year Change -90.69% 5 Year Change -81.94% Change since IPO -78.25%
Recent News & Updates
ANGLE plc Announces the Presentation of an Independent Study, Reporting on a Novel, Parsortix -Based Human Epidermal Growth Factor Receptor 2 (Her2) Workflow at the Prominent San Antonio Breast Cancer Symposium Dec 13 Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR
Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients Nov 11
First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023) Sep 29
New minor risk - Financial data availability Sep 16
ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024 Sep 04 See more updates
ANGLE plc Announces the Presentation of an Independent Study, Reporting on a Novel, Parsortix -Based Human Epidermal Growth Factor Receptor 2 (Her2) Workflow at the Prominent San Antonio Breast Cancer Symposium Dec 13 Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR
Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients Nov 11
First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023) Sep 29
New minor risk - Financial data availability Sep 16
ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024 Sep 04
Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System Aug 22
Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022) Jun 06
ANGLE plc Provides Revenue Guidance for the First Half of 2024 Jun 06
ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024 May 26
ANGLE plc Announces Publication of Study Using the Parsortix System May 17
ANGLE plc, Annual General Meeting, Jun 26, 2024 Apr 24
Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery Dec 12
ANGLE plc Launches Portrait+ CTC Kit At SABCS Dec 05
ANGLE plc Provides Earnings Guidance for the Year 2023 Nov 11
ANGLE plc Provides Earnings Guidance for the Year 2023 Nov 10
ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation Nov 09
New major risk - Revenue and earnings growth Sep 08
Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay Sep 05
Full year 2022 earnings released: UK£0.088 loss per share (vs UK£0.067 loss in FY 2021) Jun 05
ANGLE plc Announces Senior Management Appointments Jun 05
ANGLE plc Announces Board Changes May 22
Full year 2022 earnings released: UK£0.088 loss per share (vs UK£0.067 loss in FY 2021) Apr 21
ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director Jan 19
Insufficient new directors Jan 18 ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023
ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director Jan 05
ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study Nov 02
Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida Oct 25
ANGLE plc Announces Streamlining of Operations to Increase Cash Runway Oct 18
First half 2022 earnings released: UK£0.039 loss per share (vs UK£0.036 loss in 1H 2021) Sep 30
ANGLE plc Announces Positive Headline Results from Ovarian Study Sep 30
ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer Sep 28
ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US Sep 12
Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer Jul 20
ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland Jun 28
Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients May 28
Angle plc Receives FDA Clearance for Parsortix May 26
Full year 2021 earnings released: UK£0.067 loss per share (vs UK£0.065 loss in FY 2020) May 01
Insufficient new directors Apr 28 ANGLE plc, Annual General Meeting, Jun 29, 2022
ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022 Apr 20
Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis Mar 29
ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System Jan 22
ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center Jan 18
ANGLE plc Provides Update on Lab Accreditation and Ovarian Study Jan 13
Insufficient new directors Dec 06
First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020) Oct 03
ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers Sep 29
Angle plc Announces That the Health Research Institute of Santiago Sep 24
Forecast to breakeven in 2025 Jun 26
ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer Jun 18
Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission Jun 02
Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets May 13
Full year 2020 earnings released: UK£0.065 loss per share (vs UK£0.057 loss in FY 2019) May 01
ANGLE plc Announces Patient Enrolment Completed in Ovarian Cancer Clinical Verification Study Apr 26
Angle plc Provides Update on Submission for FDA Clearance of the Parsortix System Mar 04
New 90-day high: €1.09 Feb 16
Angle plc Announces Results of New Study Undertaken in Non-Small Cell Lung Cancer Feb 09
New 90-day high: €0.93 Jan 27
ANGLE plc Announces Publication of New Data Demonstrating the Performance of its Parsortix® System in a Head-to-Head Comparison with a Antibody-Based CTC System Jan 22
New 90-day high: €0.58 Jan 08
New 90-day low: €0.47 Nov 14
First half earnings released Oct 30
New 90-day low: €0.50 Oct 29
ANGLE plc Announces FDA Completes its Administrative Review and Accepts ANGLE's FDA Submission for Substantive Review Oct 20
ANGLE plc Announces Completion of FDA Submission Sep 30
ANGLE plc Announces Potential Treatment Strategy to Limit Metastasis Sep 26
ANGLE plc to Report 8 Months Period Ending Dec 31, 2019 Results on Jun 25, 2020 Sep 17
New 90-day low - €0.54 Sep 10
ANGLE plc to Report First Half, 2020 Results on Oct 29, 2020 Sep 03
Full year earnings released - €0.057 loss per share Aug 10
New 90-day low - €0.59 Jul 30 Shareholder Returns DWV DE Medical Equipment DE Market 7D 18.6% 0.9% 1.3% 1Y -33.0% -9.7% 9.0%
See full shareholder returns
Return vs Market: DWV underperformed the German Market which returned 9% over the past year.
Price Volatility Is DWV's price volatile compared to industry and market? DWV volatility DWV Average Weekly Movement 34.4% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: DWV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DWV's weekly volatility has increased from 26% to 34% over the past year.
About the Company Founded Employees CEO Website 1994 150 Andrew David Newland angleplc.com
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology.
Show more ANGLE plc Fundamentals Summary How do ANGLE's earnings and revenue compare to its market cap? DWV fundamental statistics Market cap €45.16m Earnings (TTM ) -€21.49m Revenue (TTM ) €2.41m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DWV income statement (TTM ) Revenue UK£2.02m Cost of Revenue UK£2.56m Gross Profit -UK£538.00k Other Expenses UK£17.49m Earnings -UK£18.03m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.056 Gross Margin -26.58% Net Profit Margin -890.91% Debt/Equity Ratio 0%
How did DWV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/11 10:16 End of Day Share Price 2025/01/10 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ANGLE plc is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Samuel England Berenberg Navid Malik Cavendish Historical (Cenkos Securities) Lucy-Emma Mary Codrington-Bartlett Edison Investment Research
Show 3 more analysts 
